Dr. Pleil is Senior Director, Team Lead, for Rare Disease, Hematology in the Outcomes & Evidence, Global Health & Value group at Pfizer, and currently works from the La Jolla, California research and development site. He has over 30 years of experience in conducting outcomes research in healthcare, the past 23 with Pfizer or one of its legacy companies. He has worked in the US, Sweden, and the UK in both pre- and post-marketing medical research functions across a range of therapeutic areas most recently in hematology, ophthalmology, endocrinology, rare disease, and dermatology.
He currently directs the global outcomes research program for a number of disease areas of Pfizer for both development and marketed products. The objective of his team is to deliver a portfolio of credible evidence of the economic and quality of life impacts of new products in support of regulatory submissions and to in-line product management teams at the global, regional, and country level to inform decision making and support formulary acceptance and appropriate use by patients. He has published or presented over 100 papers in journals such as Value in Health, Quality of Life Research, Medical Devices, Pharmacoeconomics and at meetings of professional societies including ARVO, ICS, ISPOR, ISOQOL, and DIA.
Dr. Pleil holds an undergraduate degree in Pharmacy from the University of Illinois, Medical Center, Chicago, and a Master’s and Doctorate in Pharmaceutical Administration from The Ohio State University. His Ph.D. minor is in international business.